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Summary
Inflammation during early lactation is common in dairy cattle, and a high degree of 
inflammation during this time has recently been associated with both lower productiv-
ity and greater risk of disease during that lactation. Early lactation treatments with two 
non-steroidal anti-inflammatory drugs were compared with a placebo treatment to 
evaluate effects on whole-lactation productivity and retention in the herd. Both meloxi-
cam and sodium salicylate increased whole-lactation milk and milk protein yields by 6 
to 9%, despite being administered for only 1 or 3 days in early lactation, respectively. 
In addition, meloxicam treatment tended to decrease the risk of cows leaving the herd 
during the lactation. These results indicate that postpartum inflammatory signals have 
long-lasting effects on lactation in dairy cattle.
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Introduction
A growing body of research indicates that systemic metabolic inflammation is elevated 
in dairy cows at parturition and that this inflammation may play a role in the develop-
ment of metabolic disorders during the transition period. Furthermore, inflammation 
has been linked to negative production outcomes. In one study, authors reported that 
cows in the highest quartile of inflammation had decreased milk production compared 
with their counterparts (30.9 kg/day vs. 24.4 kg/day in cows with low inflammation). 
In previous work at Kansas State, we administered dairy cattle with the non-steroidal 
anti-inflammatory drug (NSAID) sodium salicylate (SS) via drinking water in the week 
following calving in an attempt to prevent inflammation. Despite the fact that transi-
tion disorders were rare in either group, treatment with SS was associated with elevated 
whole-lactation milk production in older cows. Cows in their third or later lactation 
that received SS produced 21% more milk over a 305-day lactation. 
Meloxicam is another drug in the NSAID class. Previous research in lactating cattle has 
focused on its use during clinical mastitis or following assisted calving, but meloxicam’s 
effects on milk production in normal postpartum dairy cattle have not yet been investi-
gated. Considering the effects of SS on production, it is likely that meloxicam may also 
have beneficial effects on lactation. Therefore, the objective of this study was to deter-
mine if SS or meloxicam would have similar effects on whole-lactation productivity of 
dairy cows on a commercial dairy farm. 
1  Iowa State University, Ames, IA.
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Experimental Procedures
Multiparous cows (n = 51 per treatment) from a commercial dairy were enrolled in the 
study 12 to 36 hours after calving. Cows receiving SS treatment (SS) received a placebo 
bolus on day 1 of treatment and an oral drench containing 125/g/day of SS in 375 mL 
of water for 3 consecutive days beginning on day 1 of treatment. Meloxicam-treated 
cows (M) received 675 mg of meloxicam as a bolus on day 1 of treatment in combina-
tion with 3 consecutive daily drenches of 375 mL of water. Control animals (CON) 
received a placebo bolus on day 1 and water drenches. Treatments were blocked by 
mastitis at parturition (CON = 1, M = 2, SS = 2), breed (CON = 6, M = 6, SS = 4 
crossbreds; all other cows were Holsteins), dystocia (CON = 5, M = 5, SS = 6), and 
twin births (CON = 4, M = 4, SS = 3). Dystocia was defined as a calving difficulty score 
of 3 or greater.
Whole-lactation milk yield data were analyzed with a covariate of predicted transmit-
ting ability for milk production, the fixed effects of block, parity, treatment, week, and 
treatment × week interaction, and the random effect of cow. The model accounted for 
repeated measures over time with an autoregressive covariance structure. Treatment 
contrasts were evaluated using the Tukey test with significance declared at P < 0.05. Re-
moval rate from the herd and pregnancy rate were evaluated by Cox regression propor-
tional hazard analysis, and disease incidences were tested by Fisher’s exact test.
Results
Milk production responses to treatment were evaluated using two different data sourc-
es. Adjusted 305-day mature equivalent yields of milk, fat, and protein through DHIA 
testing revealed significant whole-lactation milk and protein responses to both M and 
SS treatments, representing 6 to 9% advantages for the NSAID treatments (Table 1). 
Numerical differences in fat yield were of similar magnitude (5 to 6%) but were not 
statistically significant. In addition, daily milk yield data from the farm management 
system were analyzed to assess treatment responses over time. The overall treatment 
effect on daily milk production was again significant for both NSAID treatments  
(P < 0.05, Figure 1), with a slightly larger mean response of 10 to 12%. As we observed 
in a previous study with SS, milk yields did not diverge until the second month of 
lactation, but differences in productivity then remained through the end of lactation. 
Despite the increase in productivity, body condition score monitoring throughout 
lactation revealed no differences between treatments (Table 1).
Treatments did not alter pregnancy rate on first service (mean: 23%) and had no impact 
on risk of pregnancy throughout the lactation. However, analysis of retention within 
the herd did reveal a tendency for M to improve retention compared with CON  
(P = 0.06), with SS intermediate (Figure 2). By the end of the lactation, 41% of CON 
cows had left the herd, compared with 31% for SS and only 25% for M. The only culling 
reason that differed between M and C was the code “other disease,” which accounted 
for 8 culls in CON and only 2 in M (P = 0.09); this code was used for a variety of con-
ditions, including key transition problems such as ketosis and respiratory disease.
Discussion
These results represent the fourth study demonstrating that short-term early lactation 
treatment with SS can enhance peak milk yield and the first to demonstrate similar re-
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sults with M. More importantly, this study is the first such finding with a relatively large 
sample size and with daily milk yield data to allow for accurate analysis of the lactation 
curve following treatment.
The fact that early lactation treatment (for as little as 1 day) with an anti-inflammatory 
agent can influence milk production for at least 10 months is fascinating and is not 
easily explainable. Our group is currently conducting research to explore the possibility 
that interrupting early lactation inflammation programs the mammary gland to allow 
for increased expression of milk synthesis genes as lactation proceeds.
Equally exciting is the possibility that M treatment can improve health in early lactation 
to limit the culling rate. Our sample size for this outcome was minimal, however, and 
our findings, which were of marginal significance, should be considered preliminary. In 
previous work, we carefully evaluated the effects of SS on metabolic health and found 
no evidence of improvement, but the current results seem to hint at a different response 
to M treatment, particularly in the critical first 60 days of lactation. Larger studies 
should help clarify whether these findings are meaningful or not.
Conclusions
Both M and SS increased 305-day milk and protein yields compared with CON with 
no effect on 305-day milk fat. These responses were primarily due to increased peak 
milk yield and sustained differences through late lactation and did not appear until 
the second month of lactation. Furthermore, neither treatment affected body condi-
tion score, and M tended to improve retention in the herd compared with CON. The 
long-term benefits of early lactation NSAID use are surprising and will require further 
research to understand the underlying mechanisms. Although using these approaches 
commercially is not currently legal, ongoing research may allow for nutritional or phar-
maceutical approaches to take advantage of these findings in the future.
Table 1. Whole-lactation (305-day) mature equivalent milk yield and body condition 
score (BCS) responses to early lactation treatment with anti-inflammatory drugs
  Treatment    
Item CON Meloxicam
Sodium  
salicylate SE P-value
Milk yield 
(lb)
23,091b 24,707a 25,161a 1,072 0.02
Fat yield (lb) 869 919 913 40 0.13
Protein yield 
(lb)
739b 785a 789a 31 0.03
BCS1 3.24 3.30 3.20 0.12 0.52
1 1 to 5 scale; 1 = thin and 5 = fat.
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Figure 1. Whole-lactation milk yield responses to early lactation treatments. Daily milk 
yield data were summarized by week and evaluated for the entire 44-week lactation. Both 
meloxicam (M) and sodium salicylate (SS) significantly increased daily milk yield by an 
average of 8.7 and 7.5 lb/day, respectively (P < 0.05), compared with the control. Treat-
ment differences were not significant until week 7 of lactation, then remained significant 
or marginally significant (P < 0.10) for most weeks through the end of lactation. 
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Figure 2. Survival analysis of retention in the herd after early lactation treatments. Meloxi-
cam (M) treatment tended to increase retention in the herd compared with the control 
(CON), as assessed by the Wilcoxon Chi-squared test (P = 0.06). Sodium salicylate (SS) 
did not differ from other treatments.
